ABSTRACT Objective: The current supply of acceptable donor lungs is not sufficient for the number of patients awaiting transplantation. We hypothesized that ex vivo lung perfusion (EVLP) with targeted drug therapy would allow successful rehabilitation and transplantation of donation after circulatory death lungs exposed to 2 hours of warm ischemia.
Lung compliance and oxygenation capacity after transplant with and without enhanced ex vivo lung perfusion.
Central Message
Targeted drug therapy during ex vivo lung perfusion improves outcomes after transplantation of severely injured lungs.
Perspective A significant dichotomy exists between the number of acceptable donor lungs and patients needing a transplant. Increasing use of donation after circulatory death lungs subjected to prolonged warm ischemia may decrease wait list times and mortality. Enhanced ex vivo lung perfusion with targeted drug therapy may improve outcomes.
See Editorial Commentary page 1821.
Lung transplantation is a life-saving operation for patients with end-stage lung disease but is accompanied by significant hurdles that must be overcome to ensure a positive result. Central to the discussion is the shortage of acceptable donor lungs, given the conservative acceptance criteria used by most surgeons and the increased risk of primary graft dysfunction (PGD) with transplantation of marginal lungs. 1 Considering that outcomes after lung transplantation are the worst of any solid organ, strategies to optimize lung use and increase the likelihood of a successful outcome are needed. 2 The expansion of donor acceptance criteria to include donation after circulatory death (DCD) lungs is one such approach that may substantially increase the pool of available organs. 3 Currently, DCD lungs are used in less than 2% of lung transplants per year because of the increased risk of ischemia-reperfusion (IR) injury, a major cause of PGD and a risk factor for the development of chronic graft rejection. 2, 4 The use of ex vivo lung perfusion (EVLP) before transplantation may help alleviate the resultant IR injury. 5 The use of EVLP to perform donor lung assessment followed by targeted therapeutic rehabilitation may allow for successful transplantation of otherwise-unacceptable lungs.
Targeting various cellular receptors in the lung, such as adenosine and sphingosine-1-phosphate receptors, our laboratory has shown improved outcomes and attenuation of IR injury after transplantation. 6, 7 Adenosine, a bioactive nucleoside, plays a significant role in purinergic signaling during inflammation through its interaction with 4 G protein-coupled receptors (A 1 , A 2A , A 2B , A 3 ). 8 Altering the level of adenosine receptor signaling with targeted drug delivery during EVLP may help improve outcomes after lung transplantation. The role of adenosine A 2B receptor (A 2B R) activation has been found to be both proinflammatory and anti-inflammatory in different experimental models of lung injury. [9] [10] [11] [12] Our laboratory demonstrated that it is proinflammatory and that selective antagonism of A 2B R attenuates IR injury. 13 The objective of the current study was to determine whether lungs procured after donor cardiac death and prolonged warm ischemia could be rehabilitated with EVLP and successfully transplanted, using a porcine model of lung transplantation. We hypothesized that use of EVLP with addition of an A 2B R antagonist, as targeted drug therapy during the 4-hour ex vivo perfusion period, would allow for successful rehabilitation and transplantation of DCD lungs exposed to 2 hours of warm ischemia. The use of lungs for transplantation after uncontrolled donor cardiac death in the field could increase the pool of available organs, increase the number of lung transplants per year, and decrease wait list times and mortality.
MATERIALS AND METHODS Animals and Study Groups
This study complied with the 1996 Guide for the Care and Use of Laboratory Animals as recommended by the US National Institutes of Health. The University of Virginia Animal Care and Use Committee approved the study protocol, and all animals received humane care.
Mature domestic swine of both sexes (19-42 kg) underwent hypoxic cardiac arrest, followed by 2 hours of warm ischemia before cold preservation flush and procurement of the lungs. Two hours of warm ischemia time reflects the estimated amount of time necessary to procure lungs after uncontrolled donor cardiac death in the field. Donor lungs were randomized to 4 groups (n ¼ 4/group): 4 hours of cold preservation at 4 C (Cold), 4 hours of cold preservation at 4 C with the addition of ATL802 during the reperfusion period (Cold þ ATL802), 4 hours of normothermic EVLP with Steen Solution (XVIVO Perfusion Inc, Englewood, Colo) (EVLP), or 4 hours of EVLP supplemented with ATL802 (EVLP þ ATL802) (Figure 1) . In all groups, the left lung subsequently was transplanted into a size-matched recipient and reperfused for 4 hours in vivo. ATL802 (Lewis and Clark Pharmaceuticals, Charlottesville, Va), a selective A 2B R antagonist, was given to groups Cold þ ATL802 (via external jugular vein at start of reperfusion period) and EVLP þ ATL802 (added to Steen at start of ex vivo perfusion period) as targeted anti-inflammatory drug therapy at a bolus dose of 1 mg/kg, based on previous studies. 13, 14 ATL802 currently is being used for preclinical studies only to determine the efficacy of A 2B R antagonism.
Donor-Procurement Procedure
Procurement of donor lungs was performed as previously described (Video 1). 15 Ketamine (50 mg/kg) and xylazine (5 mg/kg) were used for induction of anesthesia and intubation. Isoflurane (3%) and 1.0 fraction of inspired oxygen (FiO 2 ) were used to maintain anesthesia. Animals were ventilated (tidal volume 8 mL/kg, respiratory rate 16-20 breaths/min, positive end-expiratory pressure 5 cmH 2 O) and an initial arterial blood gas sample was analyzed. All donor animals received systemic heparin (200 U/kg; Hospira Inc, Lake Forest, Ill) and had continuous electrocardiogram monitoring in place before we clamped the endotracheal tube and induced hypoxic cardiac arrest. Donor animals underwent 2 hours of warm ischemia from the time asystole was confirmed on the cardiac monitor.
A median sternotomy was then performed and a cardioplegia cannula (Terumo Heart Inc, Ann Arbor, Mich) was inserted into the main pulmonary artery (PA) to deliver Prostaglandin-E1 (500 mg; Pfizer Inc, New York, NY) and cold Perfadex (XVIVO Perfusion Inc). A total of 1.5 liters of Perfadex supplemented with 15,000 IU of heparin was flushed through the lungs after venting the left atrial (LA) appendage and ligating the vena cava. Ice slush was introduced into the thorax to rapidly cool the lungs. The trachea was clamped mid-inspiration and the heart-lung bloc was explanted. For groups Cold and Cold þ ATL802, the heart and right lung were removed on the back table and preparation of the left bronchus, PA, and LA cuff was completed. Retrograde flush with an additional 500 mL of cold Perfadex with heparin was completed and the lungs were placed in a protective plastic bag and stored at 4 C for 4 hours. For groups EVLP and EVLP þ ATL802, the heart was removed on the back table and the trachea, main PA, and LA cuff were prepared to allow for placement of the EVLP cannulas.
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EVLP
Lungs randomized to groups EVLP and EVLP þ ATL802 underwent 4 hours of normothermic EVLP. 16, 17 A yellow cannula (XVIVO Perfusion Inc) was placed in the main PA, a green cannula (XVIVO Perfusion Inc) was sutured to the LA cuff, and a 7-0 endotracheal tube was placed into the trachea. An additional 500 mL of cold Perfadex was flushed retrograde.
EVLP was initiated on both lungs as previously described (Video 1). 18 The circuit was primed with 2 L of Steen supplemented with cefazolin (500 mg; APP Pharmaceuticals, Schaumburg, Ill), methylprednisolone (500 mg; Pfizer Inc), and heparin (10,000 IU). ATL802 was added to the ex vivo perfusate for lungs randomized to EVLP þ ATL802 and dimethyl sulfoxide (vehicle) was added for group EVLP. Surgeons were blinded as to whether the perfusate was supplemented with the treatment drug or vehicle. Flow was initiated (0.2 L/ min) and LA pressures maintained between 0 and 5 mm Hg. The perfusate was warmed to 37 C over 30 minutes. Flow was titrated up to 40% of estimated cardiac output (100 mL/kg donor body weight) and when the perfusate reached 32 C, ventilation was started (tidal volume 8 mL/kg, respiratory rate 8 breaths/min, positive end-expiratory pressure 5.0 cmH 2 O, FiO 2 0.21). A trigas mixture (86% nitrogen, 8% carbon dioxide, 6% oxygen) was used to deoxygenate the perfusate.
Samples from the PA inflow and LA outflow were collected hourly after a 15-minute challenge with 1.0 FiO 2 to measure the partial pressure of oxygen (PaO 2 ). Airway pressures were measured hourly and used to calculate dynamic compliance. After 4 hours of EVLP, lungs were flushed anterograde with cold Perfadex (500 mL) and the left lung was separated off and prepared for transplantation.
Lung Transplant Procedure
Recipient animals were anesthetized and ventilated similar to donors. A multiaccess catheter with PA catheter and an arterial catheter were placed. The animal was administered lidocaine (50 mg) and heparin (5000 IU). The transplant procedure was performed as previously described: left lateral thoracotomy, left pneumonectomy, left lung transplant (running sutures for anastomoses: end-to-end bronchial, end-to-end PA, and LA cuff to recipient LA appendage) (Video 1). 7 At the start of reperfusion, ATL802 was administered via external jugular vein injection for lungs randomized to group Cold þ ATL802.
Posttransplant Reperfusion
In vivo reperfusion was maintained for 4 hours. Airway pressure measurements and systemic arterial blood gases were performed every 30 minutes. Low-pressure lung recruitment was performed before each set of measurements. Superior and inferior pulmonary vein blood samples were obtained after 2 hours and at the completion of 4 hours of reperfusion for direct left lung PaO 2 measurements. Adequate hemodynamics and acid/base status were maintained with use of normal saline, epinephrine, and sodium bicarbonate to meet the following goals: pH 7.35 to 7.45, base excess > À5, and mean arterial pressure > 55 mm Hg. The lung was explanted after 4 hours of reperfusion and the animal euthanized.
Pulmonary Edema
Left lungs were weighed just before transplant and immediately after explant. Percent gross weight change from pretransplantation to postreperfusion was calculated to determine amount of pulmonary edema.
Cytokine Measurements
After explantation, 2 fresh tissue samples were obtained (upper and lower portion of lower lobe), flash frozen in liquid nitrogen, and stored at À80 C. FastPrep-24 (MP Biomedicals, Santa Ana, Calif) was used to homogenize tissue. Bicinchoninic acid protein assay (Pierce, Rockford, Ill) was used to determine total protein concentration in the supernatant of each homogenized tissue sample. Bronchoalveolar lavage (BAL) of the upper lobe was performed with 30 mL of normal saline, centrifuged, and stored at À80 C. A commercially available multiplex immunosorbent assay (EMD Millipore, Billerica, Mass) was used to measure levels of interleukin (IL)-1a, 1b, 4, 6, 8, 10, 12, 18, and tumor necrosis factor-a in tissue supernatant (normalized to equal protein concentrations) and BAL.
Histopathologic Assessment
The lower lobe was instilled with 10% buffered formalin via the bronchus after all fresh tissue sampling was complete and then submerged in formalin. After storage overnight, peripheral lung tissue samples (n ¼ 4/lung) were obtained, paraffin-embedded, and sectioned. One histology slide from each sample was stained with hematoxylin-eosin and 2 histology slides were used for immunohistochemistry evaluation of neutrophil infiltration.
The hematoxylin-eosin-stained slides were assessed by a masked pathologist for presence of lung injury. Each slide was scored based on the following 3 components: polymorphonuclear cells per 403 high-powered field (HPF) (0 ¼<5, 1 ¼ 6-10, 2 ¼ 11-20, 3 ¼>20), alveolar For neutrophil immunohistochemistry staining, the primary antibody used was mouse monoclonal antiporcine neutrophil antibody (MBA Biomedicals, Augst, Switzerland) and secondary antibody used was donkey anti-mouse IgG (Jackson ImmunoResearch Laboratories Inc, West Grove, Pa). After the addition of avidin-biotin complex, slides were incubated for 30 minutes at room temperature, followed by incubation with 3,3-diaminobenzidine tetrahydrochloride (Dako Inc, Carpinteria, Calif) to produce a brown precipitate, and finally counterstained with hematoxylin. 12 Five microscopic photographs of each slide were taken at 403 magnification. The number of neutrophils per HPF was counted by a masked reviewer and averaged per tissue sample to account for potential injury heterogeneity.
Statistical Analysis
One-way analysis of variance with the Bonferroni multiple comparisons test and Student t test were used to determine statistical significance between groups. Prism 6 (GraphPad Software Inc, La Jolla, Calif) was used to perform statistical calculations and all data were reported as mean AE standard error of the mean, with P value for significance of .05.
RESULTS
Lung Function
After transplantation and 4 hours of in vivo reperfusion, dynamic compliance was significantly greater in group EVLP þ ATL802 compared with the vehicle EVLP group (25.0 AE 1.8 vs 17.0 AE 2.4 mL/cmH 2 O, P ¼ .04), and compared with both non-EVLP groups (Cold: 12.2 AE 1.3, P ¼ .004 and Cold þ ATL802: 10.6 AE 2.0 mL/cmH 2 O, P ¼ .002) (Figure 2, A) . Oxygenation capacity of the transplanted lung after 4 hours of reperfusion was greatest in the EVLP group (440.4 AE 37.0 mm Hg) and significant compared with Cold (174.0 AE 61.3 mm Hg, P ¼ .037) (Figure 2, B) . There were no significant differences in final PaO 2 /FiO 2 ratios between groups Cold, Cold þ ATL802, and EVLP þ ATL802.
Before inducing hypoxic cardiac arrest, donor animals from all groups had similar PaO 2 /FiO 2 ratios (Cold: 501.7 AE 28.9, Cold þ ATL802: 510.2 AE 29.9, EVLP: 454.8 AE 17.0, EVLP þ ATL802: 490.3 AE 39.8 mmHg, P ¼ .59) with an overall mean donor PaO 2 /FiO 2 ratio of 489.3 AE 14.5 mm Hg. After the endotracheal tube was clamped, the mean time to death for all donor animals was 22.6 AE 2.0 minutes, with no difference between groups (P ¼ .2).
During the 4-hour EVLP period, no significant differences in oxygenation capacity or dynamic compliance were observed between the EVLP and EVLP þ ATL802 groups, although the hourly mean values for both parameters were consistently greater in EVLP þ ATL802 (Figure 3) . By hour 1 of EVLP, the mean PaO 2 /FiO 2 ratios for both groups were greater than 300 mm Hg (EVLP: 375 AE 23.3, EVLP þ ATL802: 427.2 AE 83.6 mm Hg) and remained elevated at the completion of 4 hours of EVLP (EVLP: 376.7 AE 61.0, EVLP þ ATL802: 384.2 AE 102.0 mm Hg).
The mean PaO 2 /FiO 2 ratios from the start of the experiment to conclusion of the 4-hour reperfusion period for the 2 untreated groups (Cold and EVLP) are shown in 
Hemodynamic Support
During the reperfusion period, intravenous normal saline, epinephrine, and sodium bicarbonate were used judiciously to maintain adequate hemodynamics and appropriate acid/base status. Recipient animals in EVLP þ ATL802 were the most stable, requiring the least amount of fluids (0.7 AE 0.1 L), epinephrine (1.2 AE 0.4 mg), and sodium bicarbonate (1.0 AE 0.0 amps) during the reperfusion period (Table 1) . 
Pulmonary Edema
Compared with Cold, lungs that underwent 4 hours of EVLP without ATL802 had significantly less weight gain from pretransplantation to postreperfusion (Cold: 120% AE 23% vs EVLP: 20% AE 20%, P ¼ .037) and trended towards significance for lungs in EVLP þ ATL802 (28% AE 10%, P ¼ .056) (Figure 5, A) . No significant differences were observed between Cold and Cold þ ATL802 (116% AE 41%) or between EVLP and EVLP þ ATL802.
Cytokine Expression
Proinflammatory cytokines were assessed in homogenized tissue supernatant and BAL fluid after the reperfusion period. A significant decrease was identified in levels of IL-12 when we compared EVLP with EVLP þ ATL802 (tissue: 132.5 AE 37.7 vs 36.3 AE 17.5 pg/mL, P ¼ .007; BAL: 360.0 AE 106.7 vs 85.0 AE 34.0 pg/mL, P ¼ .046) (Figure 5, B) . No other significant differences were identified.
Lung Injury Severity Score
Although EVLP þ ATL802 had the lowest mean composite lung injury severity score (composed of neutrophil infiltration, alveolar edema, and interstitial inflammation), there were no significant differences observed between groups (Cold: 4.31 AE 0.70, Cold þ ATL802: 3.81 AE 0.89, EVLP: 5.94 AE 0.90, EVLP þ ATL802: 2.94 AE 1.35, P ¼ .24).
Neutrophil Infiltration
Immunohistochemistry stained slides were compared between all 4 groups by the use of samples from 2 distinct lung regions, with 5 HPF counts per sample. Significantly less neutrophils were seen in group EVLP þ ATL802 compared with Cold (56.0 AE 6.7 vs 122.8 AE 16.2, P ¼ .002) and compared with EVLP (56.0 AE 6.7 vs 111.7 AE 10.0, P ¼ .012) (Figure 6 ).
DISCUSSION
Using a porcine model of left lung transplantation, in the present study we sought to determine the ability of EVLP, with and without the addition of targeted drug therapy, to rehabilitate DCD lungs exposed to 2 hours of warm ischemia. Dynamic compliance 4 hours after reperfusion was improved in lungs treated with 4 hours of EVLP supplemented with an A 2B R antagonist (ATL802), and oxygenation was improved in lungs treated with EVLP alone compared with cold preservation. After the reperfusion period, lungs that received 4 hours of EVLP, with or without ATL802, demonstrated less percent weight gain compared with lungs that underwent 4 hours of cold preservation before transplant. The combination of EVLP plus ATL802 significantly reduced neutrophil infiltration after 4 hours of reperfusion, and a decrease in the amount of IL-12 expression was observed with the addition of ATL802 compared with EVLP alone. Collectively, DCD lungs exposed to 2 hours of warm ischemia can be transplanted successfully after 4 hours of EVLP as opposed to cold preservation, and targeted drug therapy during the ex vivo perfusion period may further improve outcomes. Increasing the amount of warm ischemia time acceptable for donor lung procurement would allow for inclusion of uncontrolled DCD lungs from patients who experience cardiac arrest outside of a medical facility, with heparin administration as the only intervention possibly needed before procurement. Further investigation may show that heparin administration is not necessary if lungs are flushed with a fibrinolytic agent before EVLP. This strategy for increasing the pool of available donor lungs may shorten wait-list times and improve mortality for deteriorating patients with end-stage pulmonary disease and is gaining support clinically as the supply-demand chasm continues to widen. 19 A case report of successful transplantation after EVLP of human DCD lungs exposed to 4 hours of warm ischemia has been reported. 20 Unfortunately, longer ischemic times increase the risk of IR injury and PGD, but EVLP has been shown to be protective and beneficial when transplanting marginal donor lungs. 21 Our results support the use of EVLP compared with cold preservation alone, as the majority of the benefit seen in this study can be attributed to EVLP and not the treatment drug.
The present study employed the use of ATL802, an A 2B R antagonist, as targeted drug therapy to reduce inflammation and IR injury after transplantation. Both activation and inhibition of A 2B Rs have been shown to decrease lung inflammation. [9] [10] [11] [12] Previous work from our laboratory implicated resident pulmonary cells as opposed to bone marrow-derived cells as the location of A 2B R signaling, with a resultant decrease in cytokine expression and neutrophil activation. 9 In a mouse model of acute lung injury, Hoegl and colleagues 22 identified alveolar epithelial cells as the location of A 2B R signaling, which supports the findings from our laboratory showing attenuation of mouse lung IR with A 2B R antagonism. 13 The present study translated these findings into a large animal transplant model for the first time.
IL-12 is a proinflammatory cytokine secreted by tissue-resident macrophages and dendritic cells, which leads to increased production of interferon-g by T-helper cells. 23 IL-12, in conjunction with IL-18, an important component of inflammasome activation, has been implicated in the up-regulation of matrix degrading enzymes and T-cell infiltration in lung injury. 24 In addition, adenosine signaling has been shown to inhibit IL-12 production, which may further support the use of adenosine receptor-targeted therapies to prevent inflammation. 25 Two IL-12 antagonists, ustekinumab and briakinumab, currently are being tested in clinical trials as targeted drug therapy for immune-mediated inflammatory disease, including graft-vs-host disease. 23 Targeted treatment to downregulate IL-12 expression may be a possible adjunctive therapy, delivered during the EVLP period, to attenuate IR injury and improve outcomes after lung transplantation.
Neutrophil activation and infiltration is dependent on various signaling pathways related to both innate and adaptive immunity. We have shown previously that A 2A R activation significantly attenuates neutrophil infiltration in a mouse model of lung IR injury, as well as after transplantation in a porcine model. 15, 26 In addition, neutrophil activation has been shown to worsen acute lung injury through the involvement of A 3 Rs. 27 The present study shows evidence for a decrease in neutrophil infiltration with ATL802 treatment during EVLP. No significant difference was observed between groups Cold and Cold þ ATL802 when ATL802 was administered during reperfusion, as opposed to 4 hours before reperfusion (EVLP þ ATL802). This timing difference may impact the drug's ability to alter signaling pathways in alveolar epithelial cells and future studies are needed to better understand this effect. The resuscitative requirements of Cold þ ATL802 may be due to hemodynamic effects of systemic drug administration.
The findings are limited by low sample size, donor heparin administration, inherent variability with large animals, and the dichotomy between compliance and oxygenation values in EVLP þ ATL802. Improved oxygenation was not observed with ATL802, which may be the result of low sample size, considering one animal had significantly low oxygenation (PaO 2 /FiO 2 of 84.35). In addition, posttransplant compliance values represent both lungs. Studies further evaluating the role of A 2B Rs in acute lung injury are needed before making conclusions about the benefit of A 2B R antagonism as a treatment modality.
The use of EVLP as an assessment and rehabilitation platform to improve organ use may lead to a reduction in the critical shortage of donor lungs that meet acceptance criteria. Current functional measurements (oxygenation and compliance) used to assess lung quality may not be sufficient to fully predict success after transplantation, but measuring biomarkers, such as endothelin-1 or proinflammatory cytokines, during EVLP may improve our ability to correctly predict outcomes. 28, 29 In addition, EVLP provides an opportunity to provide targeted rehabilitative strategies based on the needs of each individual set of donor lungs. The administration of inhaled b2-agonist and neutrophil elastase during EVLP has been shown to improve outcomes after transplantation. 30, 31 Potentially more beneficial is the opportunity to provide drug treatments, such as antibiotics, at concentration levels that would otherwise be detrimental if systemically administered to the recipient. 32 In summary, the use of EVLP to rehabilitate uncontrolled DCD lungs subjected to prolonged warm ischemia is promising. Our findings of improved outcomes after transplantation with the use of EVLP and targeted drug therapy during the ex vivo perfusion period suggest that it may be possible to successfully transplant lungs procured from patients suffering cardiac death in the field. Expanding current acceptance criteria for donor lung procurement is needed to decrease wait list times and improve wait list mortality for patients with end-stage pulmonary disease. The use of EVLP to assess lung quality and administer targeted drug therapies prior to recipient allocation will allow for maximal organ use and may improve outcomes after transplantation.
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